# TMEM272

## Overview
TMEM272 is a gene that encodes the transmembrane protein 272, which is part of a family of proteins characterized by their ability to span cellular membranes. These proteins often play crucial roles in various cellular processes, including signaling and transport. While the specific functions of transmembrane protein 272 remain to be fully elucidated, it has garnered attention in the field of oncology due to its potential involvement in cancer. Notably, TMEM272 has been implicated in pediatric B-acute lymphoblastic leukemia through a fusion with the KDM4B gene, suggesting a role in the regulation of gene expression that may influence cancer progression (Gao2022Optical). Additionally, its expression patterns have been associated with prognostic outcomes in prostate cancer, highlighting its potential as a biomarker for disease risk and progression (Liu2020Identification). Despite these associations, the precise biological functions and mechanisms of TMEM272 and its encoded protein require further investigation to fully understand their implications in health and disease.

## Clinical Significance
TMEM272 has been identified as a gene of interest in various cancer studies, although its specific role and mechanisms remain underexplored. In pediatric B-acute lymphoblastic leukemia (B-ALL), a fusion gene involving TMEM272 and KDM4B was identified, resulting from an inter-chromosomal translocation between chromosomes 13 and 19. This fusion places the coding sequence of KDM4B under the control of the TMEM272 promoter, leading to increased expression of KDM4B, which may have clinical significance in leukemia (Gao2022Optical). The study suggests that such alterations in TMEM272 could be significant in the context of leukemia, although further verification is needed.

In prostate cancer, TMEM272 has been classified as a risk prognostic gene, but it is rarely reported in current studies. The limited information available suggests a need for further research to explore its potential role as a prognostic biomarker in cancer (Liu2020Identification). The expression of TMEM272 has also been noted to vary among different racial groups, indicating potential disparities that warrant further investigation (Huang2022TMEM158). Overall, the clinical significance of TMEM272 in cancer and other diseases requires additional experimental validation.


## References


[1. (Liu2020Identification) Shuang Liu, Wenxin Wang, Yan Zhao, Kaige Liang, and Yaojiang Huang. Identification of potential key genes for pathogenesis and prognosis in prostate cancer by integrated analysis of gene expression profiles and the cancer genome atlas. Frontiers in Oncology, June 2020. URL: http://dx.doi.org/10.3389/fonc.2020.00809, doi:10.3389/fonc.2020.00809. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2020.00809)

[2. (Gao2022Optical) Huixia Gao, Hanli Xu, Chanjuan Wang, Lei Cui, Xiaotong Huang, Weijing Li, Zhixia Yue, Shuo Tian, Xiaoxi Zhao, Tianlin Xue, Tianyu Xing, Jun Li, Ying Wang, Ruidong Zhang, Zhigang Li, and Tianyou Wang. Optical genome mapping for comprehensive assessment of chromosomal aberrations and discovery of new fusion genes in pediatric b-acute lymphoblastic leukemia. Cancers, 15(1):35, December 2022. URL: http://dx.doi.org/10.3390/cancers15010035, doi:10.3390/cancers15010035. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15010035)

[3. (Huang2022TMEM158) Jian Huang, Wang Liu, Da Zhang, Biyun Lin, and Benyi Li. Tmem158 expression is negatively regulated by ar signaling and associated with favorite survival outcomes in prostate cancers. Frontiers in Oncology, November 2022. URL: http://dx.doi.org/10.3389/fonc.2022.1023455, doi:10.3389/fonc.2022.1023455. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.1023455)